At four-months post-second dose, mRNA/mRNA previously infected participants had higher ACE2 inhibiting antibody concentrations (P < 0.01) against the index virus and all variants than mRNA/mRNA infection-naïve participants. This evidence concerns the gene ACE2 and infection.